Spruce Street Capital LP acquired a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 928,593 shares of the company’s stock, valued at approximately $4,322,600,000. Lexeo Therapeutics accounts for about 0.8% of Spruce Street Capital LP’s investment portfolio, making the stock its 26th largest holding. Spruce Street Capital LP owned about 1.18% of Lexeo Therapeutics at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Lexeo Therapeutics during the 2nd quarter valued at $26,717,000. Affinity Asset Advisors LLC boosted its stake in shares of Lexeo Therapeutics by 57.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after buying an additional 1,850,211 shares during the last quarter. RA Capital Management L.P. bought a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $49,650,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $47,299,000. Finally, Vestal Point Capital LP grew its holdings in shares of Lexeo Therapeutics by 37.7% in the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after acquiring an additional 1,225,000 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Wall Street Zen lowered shares of Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. lowered their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Finally, Chardan Capital raised shares of Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Lexeo Therapeutics presently has an average rating of “Buy” and a consensus price target of $18.75.
Lexeo Therapeutics Stock Performance
NASDAQ LXEO opened at $4.92 on Tuesday. The business’s fifty day moving average is $4.73 and its 200 day moving average is $5.51. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $10.99. The company has a market capitalization of $403.69 million, a PE ratio of -4.28 and a beta of 1.46.
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). On average, sell-side analysts forecast that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current year.
Insider Buying and Selling
In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer owned 377,817 shares of the company’s stock, valued at $1,692,620.16. The trade was a 6.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of Lexeo Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the transaction, the insider directly owned 82,194 shares in the company, valued at $363,297.48. This represents a 21.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 66,326 shares of company stock valued at $299,817. 2.00% of the stock is currently owned by corporate insiders.
Lexeo Therapeutics Company Profile
Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.
The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.
Featured Stories
- Five stocks we like better than Lexeo Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding LXEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Free Report).
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
